Acquired facial lipoatrophy: pathogenesis and therapeutic options

HIV-Associated facial lipoatrophy: from the advent to current knowledge.

The advent of AIDS has brought new challenges to Dermatology. Antiretroviral therapy dramatically changed the morbidity and mortality associated with HIV / AIDS, but contributed to the emergence of other new situations that require adequate approach by the dermatologist. The HIV / AIDS Associated Lipodystrophy Syndrome is multifactorial in origin, but it is strongly associated with the use of a...

Facial Lipoatrophy and AIDS

Adolescents with HIV and facial lipoatrophy: response to facial stimulation

OBJECTIVES This study evaluated the effects of facial stimulation over the superficial muscles of the face in individuals with facial lipoatrophy associated with human immunodeficiency virus (HIV) and with no indication for treatment with polymethyl methacrylate. METHOD The study sample comprised four adolescents of both genders ranging from 13 to 17 years in age. To participate in the study,...

Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.

Combination antiretroviral therapy (CART) reduces the mortality and morbidity in HIV-infected patients. However, facial lipoatrophy (FLA) is one of the well-known side-effects of this treatment and subsequently imposes major problems for HIV-infected patients. In the last decade, ample experience has been obtained with both local therapeutic options as well as possible systemic treatment option...

Drug Forecast

INTRODUCTION Human immunodeficiency virus (HIV) infection affects approximately one million persons in the U.S. alone.1 Along with recent advances in HIV treatment options, especially over the past decade, dramatic reductions in HIV-associated morbidity and mortality have been observed.2 As a result of an increase in life expectancy, however, the severity of side effects from these treatment op...